For people with cancer, chemotherapy saves lives, but for some patients, the treatment comes with a side effect—heart damage. Screening cancer drugs for cardiotoxicity has been an ongoing challenge, as heart cells don't ...
Apr 20, 2023
0
16
A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center reports benefits of chemotherapy for many patients with early-stage breast cancer with rare variant histology, or ...
Apr 18, 2023
0
2
A recent research effort led by Sarbajit Mukherjee, MD, MS, Assistant Professor of Oncology at Roswell Park Comprehensive Cancer Center, demonstrated that a new chemotherapy combination—trifluridine/tipiracil (FTD/TPI) ...
Apr 18, 2023
0
1
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone ...
Apr 16, 2023
0
4
Chemotherapy is associated with an increased risk of treatment-related heart damage, including heart failure and cerebrovascular disease, for many patients. But a new meta-analysis, presented at the American College of Cardiology's ...
Apr 14, 2023
0
2
A combination treatment approach using two chemotherapy drugs improved treatment response and progression-free survival in patients with advanced pancreatic neuroendocrine tumors, according to a recent clinical trial published ...
Apr 13, 2023
0
4
For patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen deprivation therapy (ADT), and doublet therapy ...
Apr 12, 2023
0
9
A new review paper was published in the journal Oncotarget on March 31, 2023, titled "Crosstalk between triple negative breast cancer and microenvironment."
Apr 11, 2023
0
5
A new nuclear medicine therapy can cure human non-Hodgkin's lymphoma in an animal model, according to research published in the April issue of the Journal of Nuclear Medicine. A single dose of the radioimmunotherapy, [177Lu]Lu-ofatumumab, ...
Apr 11, 2023
0
356
The development of various hypoxia-activated prodrugs (HAPs) has made considerable advances in the last few decades; however, cancer therapy using HAPs is still hindered by problems such as poor therapeutic outcomes due to ...
Apr 4, 2023
0
2
